Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
Author:
Affiliation:
1. National Institute of Infectious Diseases, Tokyo, Japan
2. National Center for Global Health and Medicine, Tokyo, Japan
3. University of Wisconsin–Madison, Madison, WI
4. University of Tokyo, Tokyo, Japan
Funder
Ministry of Health, Labour and Welfare
National Institute of Allergy and Infectious Diseases
Japan Agency for Medical Research and Development
Publisher
Massachusetts Medical Society
Subject
General Medicine
Link
http://www.nejm.org/doi/pdf/10.1056/NEJMc2201933
Reference1 articles.
1. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
Cited by 258 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical practice guideline supported administration of monoclonal antibody therapy for high-risk patients with COVID-19: Experience of a quaternary care centre;Journal of the Association of Medical Microbiology and Infectious Disease Canada;2024-09-10
2. Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients;International Journal of Infectious Diseases;2024-09
3. Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals;iScience;2024-09
4. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages;Biomedicine & Pharmacotherapy;2024-08
5. Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies;International Journal of Molecular Sciences;2024-07-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3